MKC3946


CAS No. : 1093119-54-0

MKC3946,1093119-54-0
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000392
Molecular Formula:C21H20N2O3S
Molecular Weight:380.46
Target:IRE1α
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Cat No:I000392
Cas No:1093119-54-0
Product-Name:MKC3946

is a potent and soluble IRE1α inhibitor, used for cancer research.
IC50 value:
Target: IRE1α
In vitro: MKC-3946 blocks XBP1 mRNA splicing and exhibits cytotoxicity against AML cells. MKC-3946 inhibits XBP1S expression induced by tunicamycin (TM) in NB4 cells (B) and AML sample from patients[1]. MKC-3946 prevents the splicing of the XBP1 mRNA in response to ER stress caused by mutant proinsulin production[2]. MKC-3946 is an IRE1α endoribonuclease domain inhibitor that blocks XBP1 mRNA splicing and triggers modest growth inhibition in MM cells. MKC-3946 inhibits XBP1s expression induced by Tm in a dose-dependent manner, but does not affect phosphorylation of IRE1α. MKC-3946 blocks XBP1 splicing and enhances cytotoxicity induced by bortezomib or 17-AAG. MKC-3946 (10μM) enhances ER stress-mediated apoptosis induced by bortezomib or 17-AAG, and enhances cytotoxicity of ER stressors, even in the presence of BMSCs or exogenous IL-6[3].
In vivo: MKC-3946 (100 mg/kg, i.p.) inhibits XBP1 splicing in a model of ER stress in vivo, associated with significant growth inhibition of MM cells, alone or with bortezomib. MKC-3946 significantly reduces MM tumor growth in the treatment versus control group. Inhibition of XBP1 splicing by MKC-3946 is associated with decreased MM growth in vivo, alone or in combination with bortezomib[3].


[1]. Sun H, et al. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016 Apr 5;7(14):18736-49.
[2]. Zhang L, et al. IRE1 inhibition perturbs the unfolded protein response in a pancreatic β-cell line expressing mutant proinsulin, but does not sensitize the cells to apoptosis. BMC Cell Biol. 2014 Jul 10;15:29. 
[3]. Mimura N, et al. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14;119(24):5772-81.

Recommended Products
  • CAS No. :113140-14-0
    Product Name:

    7-chloro-5-Methyl-1H-pyrazolo[4,3-b]pyridin-3-aMine

    Cat No: M130749 View details
  • CAS No. :114968-97-7
    Product Name:

    DIETHYL FLUORO(PHENYLSULFONYL)METHYLPHOSPHONATE

    Cat No: M130751 View details
  • CAS No. :107674-50-0
    Product Name:

    NORFLUOXETINE OXALATE

    Cat No: M130752 View details
  • CAS No. :19062-16-9
    Product Name:

    2-amino-1-(2,6-dichlorophenyl)ethan-1-ol

    Cat No: M130753 View details